The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced therapies.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/novel-anti-tl1a-antibody-shows-potential-crohns-disease-2025a1000un6?src=rss
Author :
Publish date : 2025-11-06 17:01:00
Copyright for syndicated content belongs to the linked Source.
